IVIG Dosing for Toxic Epidermal Necrolysis
For TEN, administer IVIG at a total cumulative dose of 2-3 g/kg divided over 3-5 consecutive days, with the most commonly recommended regimen being 1 g/kg/day for 3 days.
Evidence-Based Dosing Regimen
The optimal IVIG dosing for TEN is derived from multiple treatment experiences and guideline recommendations:
Standard Dosing Protocol
The most widely supported regimen is 1 g/kg/day for 3 consecutive days (total 3 g/kg) 1. This high-dose approach has demonstrated:
- Rapid cessation of skin detachment (mean 2.3 days)
- 88-90% survival rate
- Early treatment initiation correlates with better outcomes
Alternative Acceptable Regimens
While 3 g/kg total is preferred, other dosing strategies have shown efficacy:
- 2 g/kg total dose: Divided over 2-5 days 2, 3
- Lower doses (1.2-2 g/kg): May be considered in resource-limited settings or when combined with corticosteroids 4, 3
The UK guideline meta-analysis found that adults treated with high-dose IVIG had significantly lower mortality (18.9%) compared to low-dose IVIG (50%), though multivariate analysis showed dose may not independently predict mortality 5.
Critical Timing Considerations
Initiate IVIG as early as possible in the disease course—patients who respond best receive treatment earlier and at higher cumulative doses 1. The mean time from symptom onset to IVIG initiation in successful cases was approximately 8-9 days 2.
Infusion Rate and Administration
Based on FDA labeling for IVIG products 6:
- Initial rate: 0.01 mL/kg/min (0.5 mg/kg/min)
- Maintenance rate: Gradually increase to maximum 0.10 mL/kg/min (5 mg/kg/min) if tolerated
- Administer through separate IV line; do not mix with other medications
- Monitor vital signs throughout infusion
Important Safety Considerations
Pre-Treatment Assessment
- Check serum IgA levels—IgA deficiency increases risk of severe anaphylaxis 7
- Ensure adequate hydration to minimize renal complications 6
- Assess renal function baseline (particularly important as TEN patients may have compromised renal function)
High-Risk Populations Requiring Dose Adjustment
For patients at risk of thrombosis or renal dysfunction, use minimum effective dose at slowest tolerated infusion rate 6:
- Advanced age
- Prolonged immobilization
- Hypercoagulable conditions
- Pre-existing renal insufficiency
- Cardiovascular risk factors
Monitoring During Treatment
- Renal function (BUN, creatinine, urine output)
- Signs of thrombosis
- Blood viscosity in at-risk patients
- Platelet counts—thrombocytopenia is a rare but serious complication 8
- Hemolysis markers (particularly in non-O blood groups)
Combination Therapy
IVIG is frequently combined with systemic corticosteroids (typically methylprednisolone 1 g/day for 3-5 days) 3. The Mexican hospital series reported excellent outcomes with this combination approach, with mean hospital stay of 14.8 days and no deaths.
Pediatric Considerations
The pediatric literature shows particularly favorable outcomes with IVIG:
- Pediatric patients had 0% mortality vs 21.6% in adults in meta-analysis 5
- Dosing: 1 g/kg/day for 3 days (same weight-based dosing as adults) 9
- Even low-dose regimens (0.1 g/kg/day for 4 days) have shown success in children 10, though higher doses are preferred
Common Pitfalls to Avoid
- Delaying treatment: Early initiation is critical—don't wait for extensive skin detachment
- Underdosing: Total doses <2 g/kg may be less effective; aim for 3 g/kg when possible
- Rapid infusion in high-risk patients: Slow rates prevent renal and thrombotic complications
- Ignoring IgA deficiency: Always check before first dose
- Inadequate hydration: Volume depletion increases renal toxicity risk
- Batch variation: IVIG batches vary in their ability to inhibit Fas-mediated apoptosis 1—treatment failure may reflect batch quality rather than inefficacy of IVIG itself